.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
A 2026 study compared PreserFlo MicroShunt implantation with trabeculectomy in patients with secondary open-angle glaucoma and uncontrolled intraocular pressure. Both procedures produced large pressure reductions by 12 months, with similar rates of medication use and complete surgical success under the study's definitions. PreserFlo was associated with fewer needling interventions, while the trabeculectomy group had better visual-acuity outcomes at the reported final visit. Although retrospective and therefore vulnerable to selection bias, the study is relevant to the expanding discussion around subconjunctival microshunt procedures. For surgeons, PreserFlo may offer a less tissue-disruptive alternative in selected eyes, but postoperative management remains an important part of the intervention. Needling, bleb modulation, hypotony surveillance, and visual recovery all matter when choosing between procedures. In secondary glaucoma, where underlying pathology and previous surgery can alter conjunctival behavior and healing, the decision should be individualized. The publication adds contemporary evidence that newer subconjunctival devices can achieve pressure control approaching established filtration surgery, while also highlighting that outcomes should be assessed across efficacy, visual function, and postoperative intervention burden rather than IOP alone.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A 2026 study compared PreserFlo MicroShunt implantation with trabeculectomy in patients with secondary open-angle glaucoma and uncontrolled intraocular pressure. Both procedures produced large pressure reductions by 12 months, with similar rates of medication use and complete surgical success under the study's definitions. PreserFlo was associated with fewer needling interventions, while the trabeculectomy group had better visual-acuity outcomes at the reported final visit. Although retrospective and therefore vulnerable to selection bias, the study is relevant to the expanding discussion around subconjunctival microshunt procedures. For surgeons, PreserFlo may offer a less tissue-disruptive alternative in selected eyes, but postoperative management remains an important part of the intervention. Needling, bleb modulation, hypotony surveillance, and visual recovery all matter when choosing between procedures. In secondary glaucoma, where underlying pathology and previous surgery can alter conjunctival behavior and healing, the decision should be individualized. The publication adds contemporary evidence that newer subconjunctival devices can achieve pressure control approaching established filtration surgery, while also highlighting that outcomes should be assessed across efficacy, visual function, and postoperative intervention burden rather than IOP alone.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
